Intravenous cyclosporine-rifampin interaction in a pediatric bone marrow transplant recipient.
A 10-year-old girl with chronic myelogenous leukemia began receiving cyclosporine the day before bone marrow transplant surgery Three days after the transplant, she developed fever and neutropenia due to a Staphylococcus aureus bacteremia. Despite treatment with various antibiotics, the patient's fever persisted over the next 4 days. Intravenous rifampin was added to her antibiotic regimen of piperacillin, tobramycin, cloxacillin, and amphotericin. On day 12, the patient's blood cultures were negative and her fever had resolved; rifampin was discontinued. On day 16, the patient engrafted; she subsequently developed a grade II graft-versus-host disease of the skin and gastrointestinal tract, which responded to methylprednisolone. Her cyclosporine blood levels, which had been subtherapeutic since day 5 despite increasing intravenous dosages, were within the therapeutic range on day 21, and she was discharged 12 days later. To our knowledge, this is the first documented case of an intravenous cyclosporine-rifampin interaction that resulted in subtherapeutic cyclosporine concentrations in a child receiving a bone marrow transplant who subsequently developed acute graft-versus-host disease.
Zelunka
Elyse J
EJ
Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada. elyse.zelunka@sickkids.on.ca
D000904:Antibiotics, Antitubercular / Q000009:adverse effects* / Q000627:therapeutic use; D016470:Bacteremia / Q000150:complications; D016026:Bone Marrow Transplantation; D002648:Child; D016572:Cyclosporine / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use; D004347:Drug Interactions; D005260:Female; D005334:Fever / Q000209:etiology; D006086:Graft vs Host Disease / Q000139:chemically induced; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007262:Infusions, Intravenous; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy; D009503:Neutropenia / Q000209:etiology; D012293:Rifampin / Q000009:adverse effects* / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000150:complications / Q000382:microbiology; D013211:Staphylococcus aureus / Q000302:isolation & purification
D000904:Antibiotics, Antitubercular; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D012293:Rifampin